Navigation Links
Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing
Date:11/17/2009

SAN FRANCISCO, Nov. 17 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as lead placement agent in PolyMedix Inc.'s (OTC Bulletin Board: PYMX) $20.7 million registered public offering of 20.7 million units. The units, which were priced at $1.00 per unit, consist of one share of PolyMedix common stock and one five year warrant to purchase 0.30 of a share of PolyMedix common stock at $1.25 per share.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO)

The company announced the pricing of the public offering on November 11, 2009 and the closing on November 16, 2009. Details on the transaction can be found at PolyMedix's Web site: www.polymedix.com.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compound's small molecule mimetics of human host-defense proteins are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broadspectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with our goal of developing an antagonist drug that is safer and easier to use than current approved therapy. PolyMedix plans to file IND applications during the first quarter of 2008 in anticipation of commencing human clinical trials for both its antibiotic drug and its anticoagulant antagonist. For more information, please visit PolyMedix on its website at www.polymedix.com.

About Merriman Curhan Ford

Merriman Curhan Ford (NASDAQ: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech; Consumer, Media & Internet; Health Care; Natural Resources and Technology. For more information, please go to www.mcfco.com.

Note to Investors

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of the Company.

SOURCE Merriman Curhan Ford


'/>"/>
SOURCE Merriman Curhan Ford
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
2. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
3. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
4. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
5. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
6. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
7. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
8. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
9. Helix BioPharma announces $16.9 million private placement of common shares
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Ardea Biosciences Announces $40 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):